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  ABBREVIATIONS 
CAD - Coronary artery disease 
AP - Angina pectoris 
ACS - Acute coronary syndrome 
AMI - Acute myocardial infarction 
UA  - Unstable angina 
STEMI 
      
- ST elevation MI 
NSTEMI   -   Non ST elevation MI 
HT  - Systemic Hypertension 
DM  - Diabetes mellitus 
WBC   - White blood cell 
TC   - Total count 
P   - Polymorphs 
L   - Lymphocytes 
E  - Eosinophils 
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TB - Total bilirubin 
DB - Direct bilirubin 
SGOT      - Aspartate transferase 
SGPT       - Alanine transferase 
MPV       - Mean platelet volume 
PDW       - Platelet distribution width 
P-LCR   -    Platelet – Large cell ratio 
TC     - Total cholesterol 
TGL     - Triglycerides 
HDL     - High density cholesterol 
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INTRODUCTION 
 
 
 
Acute coronary syndrome is one of the leading cause of death and 
disability even though the development of recent advances in its medical 
science. 
Coronary heart disease may present as silent myocardial infarction, 
stable angina (AP), unstable angina (UA), myocardial infarction (STEMI 
and NSTEMI), sometimes heart failure and rarely sudden cardiac death. 
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Most important step in the management of acute coronary 
syndrome is to identify the risk factors, as identification of these risk 
factors and avoidance of these risk factors helps in the prevention of the 
development of  myocardial ischemia. 
Followed by the ruptured plaque, platelets play a vital role in the 
development of thrombus and further progression to myocardial 
infarction. Hence, by using cyclooxygenase II inhibitor and glycoprotein 
IIb/IIIa inhibitor (ticlopidine), inhibition of platelet action is used in the 
management of ACS. 
By altering one of the parameters i.e., density, size or activity, this 
leads to triggering of acute coronary syndrome and its spread. Smaller 
platelets are less adhesive, less active and tend to aggregate less easily 
than larger ones.  The prothrombotic tendency of atherosclerotic plaque 
in acute coronary syndrome is found to be increased in those who have 
increase in platelet volume and this leads to increased incidence of 
thrombus formation in such patients. 
             Our aim was to investigate significance of platelet volume indices 
in acute coronary syndrome in this study. 
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AIMS  OF THE STUDY 
 
 
 
 
 
 
 To investigate the importance and role of platelet volume indices in 
acute coronary syndrome.  
 
 
 To compare platelet volume indices in ACS (Acute myocardial 
infarction, unstable angina), stable angina pectoris and healthy 
controls.  
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REVIEW OF LITERATURE 
 
 
 
CORONARY ARTERY DISEASE is   one of the leading causes  
 
of death and disability in any part of world.  The better known 
 
          risk factors are 
 
 
1) Age  
 
2) Family history  of prior CAD 
 
3) Cigarette smoking  
 
4) Dyslipidemia   
 
5) High body mass index 
 
6) Physical inactivity 
 
7) Hypertension  
 
8) Diabetes mellitus which is accepted to be a coronary heart disease 
equivalent.  
 
          Apart from these,  novel risk factors includes 
 
 
a) Lipoprotein (a)  
 
b) Endothelial dysfunction  
 
 
c) Homocysteine  
 
 
d) C Reactive protein 
e) IL-6 and membrane bound IL-6 receptors 
13 
 
f) Increased activity of leukocyte enzyme myeloperoxidase 
g) Metabolic syndrome is considered as a new risk factor  of coronary 
heart disease. 
All these risk factor are found to be associated only with minority of ACS 
cases. Hence, it is important to detect associated risk factor to predict the 
development of ACS on an individual basis.
14 
 
 
               ACUTE MYOCARDIAL INFARCTION
1
 
 
 
Aspects of Diagnosis of Myocardial Infarction by different 
Techniques 
TECHNIQUE FEATURES 
 
 
  
 
Pathology Myocardial cell death 
 
  
 
Biochemistry 
Markers of myocardial cell death recovered 
 
from blood samples   
 
  
 
 
 
Electrocardiography Evidence of myocardial ischemia (ST and T 
 
 
wave abnormalities); evidence of loss of 
electrically functioning cardiac tissue (loss of  R 
wave) 
 
   
 
  
 
  
 
Imaging 
 
 
Cardiac wall motion abnormalities ;Reduction or 
loss of tissue perfusion 
 
 
 
  
 
 
REVISED DEFINITION OF MYOCARDIAL INFARCTION
1
 
 
 
One of the following criteria to be fulfilled for diagnosing  
 
acute, evolving, or recent MI: 
 
1) Increase or decrease in cardiac biomarkers during myocardial 
injury  along  with at least one of the following:  
a. Clinical features  of ischemia 
 
b. Presence of pathologic Q waves in the ECG  
15 
 
c. Presence of new presumed significant ST-segment changes  
or new LBBB  
d. Demonstration of  new loss of viable tissue in myocardium 
in cardiac imaging  or echocardiography showing new 
regional wall motion dysfunction   
e. Demonstration of intracoronary thrombus by autopsy or 
angiography. 
2) Tissue biopsy shows myocardial cell death.  
 
 
 HEALING OR HEALED MYOCARDIAL INFARCTION
1 
 
 
For diagnosis of  healing  or healed myocardial infarction, anyone  
 
of  the following criteria to be fulfilled: 
 
1)  Serial ECG of patients shows new pathologic Q waves. The 
patient may or may not remember previous symptoms. 
Biochemical markers of myocardial necrosis may have normalized, 
depending on the length of time that has passed since the infarction 
developed.  
2) Imaging shows loss of viable myocardium which is thinned and not 
able to contract, without nonischemic cause. 
3)  Myocardial tissue biopsy shows healed or healing infarction . 
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PATHOLOGY OF AMI
2: 
 
 
 In a coronary artery already affected by atherosclerosis  
thrombotic occlusion, leads to sudden decrease in coronary blood flow 
which results in formation of  STEMI . 
 STEMI does not occur in a gradually developing, coronary artery 
occlusion because over a period of time there is development of rich 
collateral blood flow. 
              At a site of vascular injury when there is rapid development of 
coronary artery thrombus, STEMI occurs. This injury is produced or 
favoured by risk factors such as alcohol intake, dyslipidemia, smoking and  
hypertension
2
. 
  Formation of thrombus occurs in two settings: 1) release of content 
of an atherosclerotic plaque once its surface gets disrupted   2) local or 
systemic conditions which favors thrombogenesis exist. In the presence of 
above conditions, mural thrombus is formed at this site of plaque rupture, 
and finally results in occlusion of coronary artery. Coronary plaques 
which have rich lipid core and a thin fibrous cap are found to be more 
prone to disruption by histological studies 
2
. 
 
 
17 
 
 
             At the site of plaque rupture, initially platelet monolayer is formed  
which leads to release of various agonists promoting activation of platelet 
like collagen, adenosine  diphosphate, epinephrine, 5-hydroxytryptamine. 
After activation of platelets  by these agonists  which leads to release of 
potent vasoconstrictor- Thromboxane A2, which causes further activation 
of platelet and potential resistance to fibrinolysis   is developed
2
. 
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          Production of potent vasoconstrictor Thromboxane A2 and 
activated platelet cause change in conformational in glycoprotein IIb/IIIa 
receptor and then it is converted to its functional state, which has high 
affinity for soluble adhesive proteins-fibrinogen.  Multivalent nature of 
fibrinogen helps in simultaneously binding with two different platelets at 
the same time, promoting aggregation of platelets and their cross-
linking
2
. 
          At the site of the plaque rupture, damaged endothelial cells release 
tissue factor. On exposure of tissue factor, the coagulation cascade is 
activated. Activation of extrinsic pathway of coagulation cascade leads to 
release of Factors VII and X, finally leading to the conversion of 
prothrombin to thrombin, which eventually results in formation of 
fibrinogen to fibrin. The formed thrombus occludes the involved 
coronary artery.
2
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DEFINITION
1
 
 
 
 
STABLE angina pectoris usually manifests  as a deep, ill defined 
localized chest discomfort radiating to left arm (sometimes presented  as 
pain),  which is aggravated  by physical activity  or emotional stress, and 
relieved  by rest or  nitrates . 
 
UNSTABLE angina manifests as angina pectoris (or similar type 
of ischemic discomfort) which is associated with anyone of following 
three features: 
1) Severe chest pain occurring at rest or minimal exertion, lasting for 
>20 minutes and prolonged more unless interrupted by the 
ingestion of a sublingual nitrate.  
2) New onset (within 1 month) severe frank chest pain.  
3) Follows a crescendo pattern I) that is pain that  is severe enough to 
awaken the patient  suddenly from sleep ii) that is more severe in 
nature , prolonged duration , or frequent than before.  
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       Approximately two thirds of patients with unstable angina are 
diagnosed as NSTEMI on the basis of elevated serum cardiac markers, 
like cardiac-specific troponin T or I and creatine kinase isoenzyme CK–
MB, as these are evidence of  myocardial necrosis. NSTE-ACS exhibit 
release of  troponin, and as troponin is becoming progressively more 
sensitive. Hence many patients are diagnosed as NSTEMI with a 
reciprocal reduction in the fraction with unstable angina. 
 
 
 
 
21 
 
 
PATHOLOGY OF UNSTABLE ANGINA/NSTEMI
2 
 
 
UA/NSTEMI is most commonly caused by an increase in 
myocardial oxygen demand and /or decrease in oxygen supply which is 
superadded on a lesion, usually an atherothrombotic coronary plaque, 
 that causes coronary arterial occlusion.  
Four pathological processes that may contribute to the formation of 
 
          UA/NSTEMI has been determined
2
: 
 
1)  Rupture or erosion  of atherosclerotic plaque which results in 
formation of nonocclusive  mural thrombus, is the most common 
pathology  in such patients,  NSTEMI may occur with 
embolization of  atherosclerotic debris and/or  platelet  aggregates 
downstream. 
2) Intermittent dynamic obstruction e.g., coronary artery vasospasm 
seen in Prinzmetal's variant angina (PVA)  
3) Mechanical obstruction e.g., Restenosis following PCI 
percutaneous coronary intervention or  coronary atherosclerosis 
which is  rapidly progressive  . 
 
4) Unstable Angina  which is due to increased myocardial stress 
(oxygen supply mismatch ) e.g., tachycardia, anemia. 
Single factor or combination of factor is involved.
2
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PLATELETS
3
 
 
 
 
 
           Platelets are formed from precursors megakaryocytes in the 
bone marrow . They are disc-shaped, enucleate cell fragments, 
which are released from the bone marrow into the blood 
circulation. Following a vascular injury platelet help in the 
formation of hemostatic plug that initially seals vascular defect. 
They also provide a surface for recruiting and concentrating 
coagulation factors which further enhances the coagulation 
cascade. Thus platelets play a critical role in normal haemostasis.  
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The function of platelets depends upon 
► Several glycoprotein receptors, 
 ►a contractile cytoskeleton, and 
 ►two types of  cytoplasmic  granules: a) α-Granules 
                                                               b) Dense (or δ) granule 
 
 
 
 
           After vascular injury, platelets come in contact with extra cellular 
matrix contents such as collagen and the adhesive glycoprotein vWF.  On 
contact with these proteins, platelets undergo the following physiological 
changes like: 
 
1) Platelet adhesion and shape change,  
 
 
2) Secretion (release reaction) and  
 
 
3) Aggregation  
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           Adhesion of platelets with  extra cellular matrix is mediated via 
interactions with vWF. vWF acts as a bridging connection between 
glycoprotein Ib [GpIb] (platelet surface receptors)  and exposed collagen.  
Platelets can adhere to various components of extracellular matrix like 
fibronectin but the vWF-GpIb associations are essentially necessary 
because only this association can withstand the high shear forces of 
25 
 
flowing. Thus genetic deficiencies of  vWF or its receptor  result in 
bleeding disorders depicting importance of these interactions. Deficiency 
of this receptor defect is referred to as Bernard-Soulier syndrome. 
 
 
 
   
           Soon after adhesion secretion takes place . Secretion is also called 
as release reaction. There is release of both alpha and dense granule.  
Intracellular protein phosphorylation cascade is stimulated by interaction 
of various agonists with platelet surface receptors and followed by  
degranulation. Calcium and ADP are contents of  dense-bodies and there  
26 
 
 
role in coagulation is of utmost important, because calcium acts as 
activator in  coagulation cascade, and ADP promotes further aggregation. 
ADP helps in further amplification of coagulation cascade because ADP 
promotes further ADP release.  
            Ultimately, activation of platelets results in the exposure of 
negatively charged phospholipids (mainly phosphatidylserine) on their 
outer surfaces which in turn interact with calcium and plays as nucleation 
sites for the assembly of  coagulation factors  complexes 
3
. 
             Platelet aggregation is followed by adhesion and release of 
granule. Like ADP that amplifies platelet aggregation, Thromboxane A2 
another platelet-derived vasoconstrictor which also amplifies platelet 
aggregation. Thus the three processes adhesion, secretion and  
aggregation results in the formation of the primary hemostatic plug. This 
initial cascade of aggregation is reversible, but with  generation of 
thrombin, simultaneous activation of the coagulation cascade  results in 
stabilization of  the platelet plug . Thrombin causes stabilisation of 
platelet plug in two ways: 
27 
 
 
 
 
(1) Thrombin causes further platelet aggregation and activation 
by binding with protease-activated receptor on the platelet membrane and  
also by its interaction with ADP and TxA2 . The  cytoskeleton  of platelet  
plays a major role in activation of platelet by forming  an irreversibly 
fused mass of platelets,  which results in the definitive secondary 
haemostatic plug
3
. 
 
     (2)  Thrombin mediates the  conversion of  fibrinogen to fibrin, 
which functionally cements  the platelets in place. 
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The interaction between platelets and endothelium has a profound 
impact on clot formation. Endothelial cell-derived factor- Prostacyclin 
(PGI2)  is a potent vasodilator and inhibits platelet aggregation, whereas   
TxA2 is a potent vasoconstrictor and activates platelet aggregation. 
Effects of  PGI2 and TxA2 should be well balanced  effectively as they 
modulate  platelet and vascular wall function.  
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             Eventually by the effect of the above endothelial cell-derived 
factor, platelet aggregation is prevented and hemostatic plug formation 
takes place. Irreversible cyclooxygenase inhibitor – aspirin has the ability 
to permanently block platelet TxA2  synthesis and hence it is clinically 
utilised in persons at risk for coronary thrombosis. Aspirin inhibits 
endothelial PGI2 production, thereby prevents platelet plug formation but 
endothelial cells can overcome this blockage by resynthesizing  
cyclooxygenase  enzyme.  
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MEAN PLATELET VOLUME 
 
 
 
Platelets are heterogeneous regarding their size, density, and 
functional activity
19
. Alterations of these parameters results in pulling the 
trigger of acute coronary syndrome and its spread
20
. 
 
In ACS, thrombogenic phenomenon begins with the rupture of 
atherosclerotic plaque. The functions of circulating platelets are necessary 
for the thrombogenic phenomenon in ACS
21
. 
Test like in vitro aggregometry, has found significant difference in 
the function of large and small platelets. Compared  to smaller platelets   
large  platelets  are more adhesive and  aggregative. Large platelets 
contain higher levels of P-selectin and glycoprotein IIIa which are 
procoagulatory surface proteins. Thus in ACS, prothrombotic tendency of 
atherosclerotic plaque  increases proportionality with increase in  mean  
platelet volume and is also associated with increased risk of intracoronary 
thrombus formation in acute myocardial infarction cases
5
. 
Platelet volume has a major role in platelet function and activation. 
More secretary granules and mitochondria are present in larger platelets 
compared to small platelets thus large ones are more active.  
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Larger platelets are hyperactive leading to the formation and 
embolisation of intracoronary thrombus and thus large platelet promotes 
the emergence of acute coronary syndrome. 
Thus Increased platelet volume measured after MI, has been 
suggested to be a risk factor for further ACS episodes. 
            Along with the other cardiac biomarkers, usefulness of MPV is 
such that it can to be used as a routine test for the risk stratification of 
ACS in patients admitted to the ICCU. Major advantage of PVI is that it 
is a simple and inexpensive laboratory measurement. 
Due to alterations in the autonomic nervous system MPV has great 
diurnal and nocturnal variation as found out by studies. 
A study also showed that there is a correlation between 
sympathetic nervous activity and the MPV in AMI patients as the 
adrenergic system exerts its effect on thrombopoiesis in bone marrow and   
peripheral platelet activation. 
 
1) The effects of the adrenergic system on platelet activation take 
place in two ways in the peripheral circulation. Alpha2-
adrenoreceptor activation results in change of the shape of 
platelets and hence increases MPV. 
  
32 
 
2) Following exercise or following administration of adrenaline, 
larger, activated platelets which are sequestered in the spleen 
are released into the circulation leading to the increase in MPV 
following  physical effort
46
.  
It has been shown that during admission in AMI patients high MPV can 
be used as an independent risk factor for risk stratification regarding 
impaired perfusion and associated death. 
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MEAN PLATELET VOLUME
45 
 
 
The mean platelet volume result is calculated by an automated 
analyser. MCV is a calculation of the mean size of individual red blood 
cells  whereas MPV  is a calculation of the mean size of platelets. 
 
Normal Range7.5-11.5 femtolitre 
 
 
If MPV is reduced 
 
 
It indicates the platelets are smaller than usual size. They are 
referred to as Micro thrombocytes
45
. 
 
CAUSES:- 
 
1. Aplastic Anemia- 
 
An acquired disorder in which the new blood cells production is 
halted in the bone marrow. 
 
2. Wiskott-Aldrich Syndrome- 
 
An inherited immune deficiency disorder. 
 
 
3. Thrombocytopenia-absent radii (TAR Syndrome) - 
 
A rare inherited disorder in which there is absence of the radius 
bones in the forearms associated with low platelet count. 
 
4. Storage Pool Disease
34 
 
 
If MPV is increased 
 
It indicates that platelets are larger than normal. They are referred 
to as Macro thrombocytes
45
. 
 
CAUSES:- 
 
1. Idiopathic Thrombocytopenic Purpura- 
 
A bleeding diathesis in which there is disorder of blood clotting  
 
mechanism. 
 
 
2. Bernard-Soulier Disease - 
 
An inherited disorder where the function of platelets are deficient 
in help to adhere to the walls of the blood vessels. 
 
3. May-Hegglin Anomaly - 
 
A rare, inherited disorder in which there are abnormally large 
platelets. 
 
4 Greater risk of heart attacks and stroke- 
 
As there are increased numbers of hyperaggregable large platelets 
there is increased risk of ischemic events. 
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MPV is found to be elevated in patients with acute coronary 
syndrome at the time of admission in coronary care unit , and it is being 
hypothesised that changes in the entire megakaryocytic-platelet-
haemostatic axis precedes acute coronary events. 
 
It s postulated that MPV increases before MI for three reasons
46
: 
 
1)   The life span of platelets is eight days approximately, and the increase 
in MPV is noted within the first 12 hr of admission  
2)  The increase in MPV persists beyond six weeks after discharge during 
which time the infarct would be largely healed. 
 
3)   Log normality of platelet volume is preserved.  
 
 
 
An alpha1-adrenoreceptor antagonist Doxazosin, or an angiotensin 
II receptor blocker Losartan have been found to exert therapeutic effects 
on platelet size in vitro based on the observations of recent studies which 
have  not yet been confirmed. In a study conducted  with small number of  
30 patients, revealed that  platelet aggregation inhibitors have no effect on 
MPV values.
36 
 
 
 
 
 
 
 
 
 
 
MATERIALS  
AND  
METHODS 
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                  MATERIALS AND METHODS 
 
 
SETTING 
 
This study is conducted in Cardiology department (CCU & OP) 
and Department of Medicine, Government Royapettah Hospital in 
collaboration with Department of  Pathology and Biochemistry. 
 
ETHICAL APPROVAL 
 
Obtained. 
 
STUDY DURATION 
 
This study was conducted over a period of 7 months from January 
2015 to August 2015. 
 
STUDY  POPULATION 
 
Patients admitted with acute coronary syndromes in coronary care 
unit, stable angina pectoris patients followed in cardiology op and 
medical op and healthy controls in medical wards and medicine op in 
Government Royapettah Hospital. 
SAMPLING 
 
Patients are allotted by convenience sampling in each group. 
 
TYPE OF STUDY 
 
It is a hospital based cross sectional study. 
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INCLUSION CRITERIA 
 
          Patients presenting with chest pain in the casualty/Medical OPD are 
evaluated and divided according to clinical manifestations, ECG and echo 
into four groups. 
1. Non cardiac chest pain with no evidence of IHD in history, physical 
examination, ECG and Echo constitute normal group (controls). 
2. Patients with clinical manifestations, ECG and Echo suggestive of 
UA/NSTEMI. 
3. Patients with clinical manifestations, ECG and Echo suggestive of 
STEMI. 
4. Patients with clinical manifestations, ECG and ECHO suggestive of 
chronic stable angina 
 
EXCLUSION CRITERIA 
 
 
1. Patients with bleeding disorders, blood dyscrasias, 
preeclampsia, sepsis. 
2. Patients with history of  blood transfusion recently (within 6 
weeks) 
3. Patients with history of major operations ,trauma recently 
(within 6 weeks) 
4. Patients who are receiving drugs which can cause 
thrombocytopenia 
5. Patients with infections known to cause thrombocytopenia. 
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SAMPLE SIZE: The study will include a total of 100 patients. 
 25 patients with non cardiac chest pain 
 25 patients with UA/NSTEMI 
 25 patients with STEMI 
 25 patients with chronic stable angina 
 
METHODS 
 
         Informed consent will be taken from all patients included in this 
study. Blood samples would be drawn at the time of admission before 
initiation of treatment. Estimation of platelet count, MPV, PDW and PLCR 
will be calculated in all patients included in this study(by Hemogram). 
Processing of  blood samples would be done within 30 minutes of  blood 
collection using an autoanalyser. 
         Clinical history will include 
1. age  
2. sex 
3. history of precipitating factors like physical exercise  
4. emotional stress   
5. medical disorder  
6. surgical disorder 
7. past history of diabetes 
8. hypertension 
9. smoking 
10. alcohol 
11. previous episodes of chest pain. 
      Clinical examination will include vitals, general examination and 
systemic examination including detailed examination of CVS. 
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Investigations include 
a. Complete hemogram (including MPV, PDW and PLCR) 
using an autoanalyser. 
b. RBS, urea, creatinine, bilirubin  
c. Serum lipid profile in the fasting state. 
d. ECG 
e. Echocardiography  
On the basis of history, physical examination and investigations patients 
will be divided into to four groups – those with  
                             STEMI , 
                            UNSTABLE ANGINA/NSTEMI ,  
                            NON CARDIAC CHEST PAIN AND 
                            CHRONIC STABLE ANGINA.  
The platelet indices of the four groups will be compared. 
 
EQUIPMENTS AND MATERIALS 
Facilities for ECG are available in the casualty itself.  Hemogram will be 
done free of cost in the pathology  lab of  Govt. Royapettah Hospital . 
Facilities for echocardiography are available in the cardiology department. 
 
STATISTICAL ANALYSIS 
 
The tests used are 
 
a. ANOVA 
 
b. Chi-square test and 
 
c. t test 
 
Data were collected and statistical significance was analysed. 
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STATISTICAL 
REPORTS  
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RESULTS 
 
 
                           
SEX AND ACS 
 
 
 
TABLE 1.1: 
 
 
    SEX FREQUENCY PERCENTAGE 
   
MALE 40 80% 
   
FEMALE 10 20% 
   
TOTAL 50 100% 
   
 
 
 
 
DIAGRAM 1: 
 
 
 
 
SEX 
MALE
FEMALE
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TABLE 1.2: 
 
 
 
 
SEX  MEAN   N  STD  STD 
 
        DEVIATION ERROR OF 
 
            MEAN 
 
             
 
MALE  9.570     40  .8715 .1378 
 
             
 
FEMALE  9.960   10   .8113 .2566 
 
             
 
 
 
TABLE 1.3:  
 
          
 
 
 
 
Sig 
 
MPV P Value 
 
  
 
  
 
 
Between 
Groups 
0.206 (NOT SIG ) 
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AGE GROUP AND ACS 
 
 
 
TABLE 2.1 
 
  AGE GROUP FREQUENCY PERCENTAGE 
   
Below 40 10 20% 
   
41-50 26 52% 
   
51-60 11 22% 
   
Above 60 3 6% 
   
TOTAL 50 100% 
   
DIAGRAM 2 : 
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TABLE 2.2: AGE GROUP AND MPV 
 
 
 
  
 
MPV P Value 
 
  
 
  
 
 
Between 
Groups 
0.765 (NOT SIG) 
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TYPE OF ACS BASED ON ECG 
 
 
 
TABLE 3: 
 
 
 
MI FREQUENCY PERCENTAGE 
   
AWMI 12 25% 
   
ASMI 5 10% 
   
IWMI 4 8% 
   
IW + PWMI 4 8% 
   
UA 25 50% 
   
TOTAL 50 100% 
   
 
 
 
DIAGRAM 3: 
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UA
AWMI
ASMI
IWMI
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HYPERTENSION AND ACS 
 
 
 
TABLE 4.1: 
 
 
 
HYPERTENSION FREQUENCY PERCENTAGE 
   
YES 31 62% 
   
NO 19 38% 
   
 
 
 
DIAGRAM 4: 
 
 
 
 
 
 
 
 
 
 
 
 
 
HYPERTENSIVE 
HYPERTENSIVE
NON-HYPERTENSIVE
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       TABLE 4.2:  HYPERTENSION AND MPV 
 
       
MPV 
 
 
Sig 
 
p value 
  
  
  
Between 0.346 (NOT SIG ) 
Groups  
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DIABETES AND ACS 
 
 
 
TABLE 5.1: 
 
 
 
         DIABETIC FREQUENCY PERCENTAGE 
   
YES 34 68% 
   
 NO 16 32% 
   
 
 
DIAGRAM 5: 
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TABLE 5.2: DIABETES AND MPV 
 
                        
 
 
 
                  MPV 
Sig 
 
 P value 
 
  
 
  
 
Between 
 
0.959 ( NOT SIG) 
 
Groups  
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PRIOR CAD AND ACS 
 
 
 
TABLE 6.1: 
 
 
 
PRIOR CAD FREQUENCY PERCENTAGE 
   
        YES 11 22% 
   
         NO 39 78% 
   
   
 
 
 
 
 
 
DIAGRAM 6: 
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TABLE 6.2: PRIOR CAD AND MPV 
 
 
 
 
MPV Sig  
 
P value 
 
  
   
Between 0.054 (SIG)  
groups   
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SMOKING AND ACS 
 
 
TABLE 7.1: 
 
 
 
  SMOKING FREQUENCY PERCENTAGE 
   
YES 28 56% 
   
NO 22 44% 
   
 
 
 
DIAGRAM 7: 
 
 
 
     
SMOKING 
SMOKER
NON-SMOKER
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TABLE 7.2: SMOKING AND MPV 
 
 
 
MPV Sig 
 
 
P value 
 
 
 
  
 
Between 0.701 ( NOT SIG) 
 
groups  
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ALCOHOL AND ACS 
 
 
TABLE 8.1: 
 
 
 
 
 
 
 
 
 
 
DIAGRAM 8: 
 
 
 
 
 
ALCOHOL 
ALCOHOLIC
NON-ALCOHOLIC
    ALCOHOL FREQUENCY PERCENTAGE 
   
        YES 37 74% 
   
         NO 13 26% 
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TABLE 8.2: ALCOHOL AND MPV 
 
 
 
MPV Sig 
 
 
P value 
 
 
 
  
 
Between 0.765 (NOT SIG) 
 
Groups  
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KILLIP CLASSIFICATION 
 
 
 
TABLE 9.1: 
 
 
Killip Frequency Percentage Mortality Percentage 
 
Class      
 
     
 
   1 10 40% 0 0% 
 
     
 
   2 9 36% 2 67% 
 
     
 
   3 4 16% 1 33% 
 
     
 
   4 2 8% 0 0% 
 
     
 
Total 25 100% 3 100% 
 
     
 
 
 
DIAGRAM 9: 
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TABLE 9.2: KILLIP CLASSIFICATION AND MPV 
 
 
 
MPV Sig 
 
 
P value 
 
 
 
  
 
Between 0.252 ( NOT SIG) 
 
groups  
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MEAN PLATELET VOLUME IN COMPARISON 
 
TABLE 10.1: 
 
 
 
GROUP 
MEAN PLATELET 
VOLUME  (Femolitre) 
  
MI 
 
9.8 
  
UNSTABLE ANGINA 
 
9.5 
  
 
STABLE ANGINA 
 
8.4 
  
  
  
HEALTHY CONTROL 8.2 
  
 
 
DIAGRAM 10: 
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TABLE 10.2:  MPV WITHIN GROUPS 
  
ANOVA TEST 
 
 
MPV Sig 
 
 
P value 
 
 
 
  
 
Between <0.001 
 
groups  
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ECHOCARDIOGRAPHY FINDINGS IN ACS 
 
TABLE 11.1: 
  
Echo Frequency Percentage 
   
NO RWMA 13 26% 
   
RWMA 10 20% 
   
MILD LV 9 18% 
DYSFUNCTION   
   
MOD LV 11 22% 
DYSFUNCTION   
   
SEVERE LV 7 14% 
DYSFUNCTION   
   
TOTAL 50 100% 
   
 
RWMA- REGIONAL WALL MOTION ABNORMALITY 
 
DIAGRAM 11: 
 
 
    
ECHOCARDIOGRAPHY FINDINGS 
NO RWMA
RWMA
MILD LV DYSFUNCTION
MOD LV DYSFUNCTION
SEVERE LV DYSFUNCTION
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TABLE 11.2: ECHO AND MPV 
 
 
 
MPV Sig 
  
  
Between .816 (NOT SIG) 
groups  
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MEAN PLATELET VOLUME IN ACS 
 
TABLE 12.1: 
  
 
  
 
GROUP 
MEAN PLATELET 
 
VOLUME(FEMTOLITRE)   
 
  
 
AWMI 10.0 
 
  
 
ASMI 9.8 
 
  
 
IWMI 9.0 
 
  
 
IW+PWMI 10.2 
 
  
 
UA 9.4 
 
  
 
 
 
DIAGRAM 12: 
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TABLE 12.2: 
 
 
MPV Sum of Df Mean F Sig 
 squares  square   
      
Between 5.327 4 1.332 1.906 
       0.126 
(NOT SIG) 
groups      
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PLATELET COUNT IN COMPARISON 
 
 
TABLE 13: 
 
 
PLATELET COUNT MEAN cells/dl 
  
MI 2,10,840 
  
UNSTABLE ANGINA 2,21,760 
  
STABLE ANGINA PECTORIS 2,26,720 
  
  
HEALTHY CONTROLS 2,27,040 
  
TOTAL 2,21,590 
  
 
 
 
 
DIAGRAM 13: 
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MPV PDW P-LCR IN COMPARISON 
 
 
 
DIAGRAM 14: 
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MPV PDW P-LCR IN COMPARISON 
 
 
TABLE 14.1: 
 
 
GROUP MPV(fl) PDW% P-LCR 
    
MI 9.8 14.3 29.4 
    
UNSTABLE ANGINA 9.5 14.8 27.8 
    
STABLE AP 8.4 12.7 24.6 
    
HEALTHY CONTROLS 8.2 13.1 24.4 
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TABLE 14.2:  PLATELET VOLUME INDICES WITHIN GROUPS 
 
 
ANOVA TEST 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PLATELET  VOLUME  INDICES SIG P VALUE 
MPV Between groups 
<0.001 
(HIGHLY SIG) 
PDW Between groups 
<0.001 
(HIGHLY SIG) 
             P-LCR Between groups 
<0.001 
(HIGHLY SIG) 
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COMPARISON OF MPV PDW P-LCR BETWEEN 
 
CASES AND CONTROLS 
 
 
TABLE 15.1: 
 
 
 
        
MEAN VALUE  
MPV(fl) PDW% P-LCR 
    
CASES ( MI GROUP  AND  
UNSTABLE ANGINA GROUP) 9.6 14.5 28.6 
    
CONTROL (STABLE ANGINA 
AND HEALTHY GROUP) 8.3 12.9 24.5 
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TABLE 15.2:  COMPARISON OF MPV PDW P-LCR BETWEEN  
 
CASES AND CONTROLS 
 
 
  
t TEST    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
PLATELET  VOLUME  INDICES SIG P VALUE 
MPV Between groups 
<0.001 
(HIGHLY SIG) 
PDW Between groups 
<0.001 
(HIGHLY SIG) 
             P-LCR Between groups 
<0.001 
(HIGHLY SIG) 
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OUTCOME AND DEATH 
            
TABLE 16.1: 
 
 
 
 
 
 
 
 
 
DIAGRAM 16: 
 
 
     
          
 
  
OUTCOME 
IMPROVED
EXPIRED
  OUTCOME FREQUENCY PERCENTAGE 
   
IMPROVED 45 90% 
   
  EXPIRED 5 10% 
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TABLE 16.2:  
 
 
 
MPV Sig 
  P value 
  
Between 
 
    0.606(NOT SIG) 
 
groups  
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 MPV AND DEATH 
 
 
 
TABLE 17: 
 
 
  PATIENT NAME DEATH MPV(femtolitre) 
   
DEVADASS IW+PWMI 10.8 
   
JEYA IW + PWMI 10.4 
   
KUMAR ASMI 10.2 
   
ASHOK UA 8.4 
   
GUNASEKARAN UA 9.4 
   
 
 
DIAGRAM 17: 
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COMPARISON OF GROUPS BY MPV 
 
 
TABLE 18: 
 
 
 
 
 
 
P VALUE 
 
SIG/NOT SIG 
 
 
 
 
 
 
 
 
MPV 
 
MI GROUP 
9.8 ± 0.9 
 
UNSTABLE 
GROUP 
9.5 ± 0.8 
 
0.284 
 
NOT SIG 
UNSTABLE 
GROUP 
9.5 ± 0.8 
STABLE GROUP 
8.4 ± 0.6 
<0.001 HIGHLY  SIG 
STABLE GROUP 
8.4 ± 0.6 
HEALTHY 
GROUP 
8.2± 0.6 
0.817 
 
NOT SIG 
HEALTHY 
GROUP 
8.2± 0.6 
MI GROUP 
9.8 ± 0.9 
<0.001 HIGHLY  SIG 
 
UNSTABLE 
GROUP 
9.5 ± 0.8 
 
HEALTHY 
GROUP 
8.2± 0.6 
 
<0.001 
 
HIGHLY  SIG 
 
MI GROUP 
9.8 ± 0.9 
 
STABLE GROUP 
8.4 ± 0.6 
 
<0.001 
 
HIGHLY  SIG 
 
 
 
SIG- SIGNIFICANT 
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COMPARISON OF GROUPS BY PDW 
 
 
 
TABLE 19: 
 
 
 
 
 
 
P VALUE 
 
SIG/NOT SIG 
 
 
 
 
 
 
 
 
PDW 
 
MI GROUP 
14.3 ± 0.2 
 
UNSTABLE 
GROUP 
14.8 ± 0.7 
 
0.752 
 
NOT SIG 
UNSTABLE 
GROUP 
14.8 ± 0.7 
STABLE GROUP 
12.7 ± 0.2 
0.001 SIG 
STABLE GROUP 
12.7 ± 0.2 
HEALTHY 
GROUP 
13.1 ± 0.2 
0.877 
 
NOT SIG 
HEALTHY 
GROUP 
13.1 ± 0.2 
 
MI GROUP 
14.3 ± 0.2 
0.133 NOT  SIG 
 
UNSTABLE 
GROUP 
14.8 ± 0.7 
 
HEALTHY 
GROUP 
13.1 ± 0.2 
 
0.010 
 
HIGHLY  SIG 
 
MI GROUP 
14.3 ± 0.2 
 
STABLE GROUP 
12.7 ± 0.2 
 
0.021 
 
SIG 
 
 
SIG- SIGNIFICANT 
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COMPARISON OF GROUPS BY P-LCR 
 
 
 
TABLE 20: 
 
 
 
 
 
 
 
P VALUE 
 
SIG/NOT SIG 
 
 
 
 
 
 
 
 
P-LCR 
 
MI GROUP 
29.4 ± 1.0 
 
UNSTABLE 
GROUP 
27.8 ± 0.6 
 
0.258 
 
NOT SIG 
UNSTABLE 
GROUP 
27.8 ± 0.6 
STABLE GROUP 
24.6 ± 0.6 
0.002 SIG 
STABLE GROUP 
24.6 ± 0.6 
HEALTHY 
GROUP 
23.4± 0.3 
0.992 
 
NOT SIG 
HEALTHY 
GROUP 
23.4± 0.3 
 
MI GROUP 
29.4 ± 1.0 
<0.001 HIGHLY  SIG 
 
UNSTABLE 
GROUP 
27.8 ± 0.6 
 
HEALTHY 
GROUP 
23.4± 0.3 
 
0.001 
 
HIGHLY  SIG 
 
MI GROUP 
27.8 ± 0.6 
 
STABLE GROUP 
24.6 ± 0.6 
 
<0.001 
 
HIGHLY SIG 
 
 
SIG- SIGNIFICANT 
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DISCUSSION 
 
 
 
In our study, four groups were taken into account such as MI 
group, unstable angina, stable angina pectoris and healthy controls. Cases 
(acute coronary syndrome) include MI group and unstable angina. 
Controls include stable angina pectoris and healthy controls. 
In our study the significance of platelet volume indices in cases 
(acute coronary syndrome) is the prime concern and they were compared 
with controls (stable angina pectoris and healthy controls). 
           Blood samples for platelet volume indices were taken at the time of 
admission in cases. Platelet volume indices was analysed by automatic 
analyzer. Statistical significance in Platelet volume indices was analysed 
between cases and controls. 
 
AGE AND MPV IN ACS 
 
 
Mean age of patients who sustained ACUTE CORONARY 
SYNDROME was 45 years in my study. No statistical significance was 
noted in MPV between age groups in relation to cases (p value is .765 i.e. 
>.05). 
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SEX DISTRIBUTION AND MPV IN ACS: 
         Out of 50 patients 40 (80%) were males and 10 (20%) were female. 
No statistical significant significance was detected in MPV between the 
two sexes in relation to ACS (p value is .206 i.e. >.05). 
 
TYPE OF ACS 
          In my study, out of 50 ACS patients, 12 (25%) had AWMI, 5  
(10%) had ASMI, 4(8%) had IW+PWMI and 25 (50%) had UNSTABLE  
ANGINA. 
HYPERTENSION AND MPV IN ACS 
             31(62%) were hypertensive and 19(38%) were non-hypertensive. 
No statistical significance was detected in MPV between the hypertensive 
and non-hypertensive in relation to ACS (p value is 0.346 i.e. >.05). 
 
DIABETES AND MPV IN ACS 
 
34 (68%) were diabetic and 16(32%) were non diabetic. No 
statistical significance was detected in MPV between diabetics and non-
diabetics in relation to ACS (p value is .959 i.e. >.05). 
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SMOKING AND MPV IN ACS 
 
28(56%) were smoker out of 40 males. None of the females were 
smokers. 22(44%) were non-smoker. No statistical significance was 
noted in MPV between smokers and non-smokers in relation to ACS (p 
value is .106 i.e. >.05) 
 
ALCOHOL AND MPV IN ACS 
 
37 (74%) were consuming alcohol and 13(26%) did not consume 
alcohol. No statistical significance was detected in MPV between 
alcoholics and non-alcoholics in relation to ACS (p value is .765 i.e. 
>.05). 
 
KILLIP CLASSIFICATION AND MPV IN ACUTE  
MYOCARDIAL INFARCTION 
           Patients were divided into 4 based on this classification. 10 (40%) 
were in Class 1, 9 (36%) were in class 2, 4 (16%) were in class 3 and 
2(8%) were in class 4. No statistical significance was detected in MPV 
between the killip groups in relation to ACS (p value is .252 i.e. >.05). 
 
ECHO FINDINGS AND MPV IN ACS 
 
In our study, echo findings were analysed. In this, 13 (26%) had 
NO RWMA, 10(20%) had RWMA, 9(18%) had MILD LV 
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DYSFUNCTION, 11(22%) had MODERATE LV DYSFUNCTION, 
7(14%) had SEVERE LV DYSFUNCTION. No statistical significance 
was detected in MPV between echo findings in relation to ACS (p value 
is .816 i.e. >.05). 
 
MEAN PLATELET VOLUME 
 
           Our study showed that mean platelet volume (hectolitres) in MI 
group was 9.8, UNSTABLE ANGINA group was 9.5, STABLE AP 
group was 8.4 and HEALTHY CONTROLS was 8.2. Mean platelet 
volume were comparable between four groups with high statistically 
difference of 0.000 (<0.5).  
    Mean platelet volume were comparable between Cases (acute 
coronary syndrome) includes MI group and unstable angina and Controls 
includes stable angina pectoris and healthy controls with high statistically 
difference of 0.000 (<0.5).  
In a similar study
4
 which compared AMI and unstable AP, MPV in 
unstable AP was 9.0 ± 1.0 fl and 8.9 ± 0.8 fl in acute myocardial 
infarction. No statistical significance was detected in MPV between these 
(difference p=0.999) two groups.  
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In control group was 7.2 ± 0.6 fl and in stable AP patients, MPV 
was 7.5 ± 0.6 fl, respectively. No statistical significance was detected in 
MPV between these two groups (difference p=0.126). 
When stable angina pectoris and control groups were compared to 
each of AMI cases and unstable angina, it was found that MPV was 
increased in AMI cases and unstable angina. 
Here in our study too, there is statistically significant difference 
between cases (MI group and UNSTABLE ANGINA) and other two 
groups which is similar to the above cited study
4
. 
In the study by Ender et al
10
, it is concluded that MPV was found 
to be increased who those with AMI patients on comparison with stable 
AP patients and this result was consistent with our study too. 
In the study comparing AMI patients to control groups and stable 
angina pectoris conducted by Kishk et al
24
 revealed that lower platelet 
count and higher MPV to be associated with AMI group than the stable 
angina pectoris and control groups. In our study, mean platelet volume 
was higher in AMI group and platelet count was also reduced than others. 
          In another study conducted by Puzzili et al
36
 , concluded that MPV 
was higher side in unstable angina pectoris patients, compared to control 
groups and  stable angina  which is consistent with our study. 
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MEAN PLATELET VOLUME IN ACS 
 
In our study mean platelet volume in AWMI was 9.6, ASMI was 
9.6, IWMI was 9.7, IW+PWMI was 10.0, IW+PW+RVMI was 9.8 and 
UA was 9.5. No statistical significance was detected in MPV between the 
various types of ACS (p value is .889 i.e. >.05). 
 
PLATELET COUNT AND ACS 
 
         In our study, platelet counts in four groups were analysed. Mean    
value  in  AMI group was 2,10,840 cells/dl, UA group was 2.21,760  
STABLE AP was 2,26,720  cells/dl and HEALTHY CONTROLS was  
2,27,040  cells/dl. While comparing between the groups there was no  
statistical difference  between any groups. But in our study we compared   
mean  platelet  count  in  AMI patients to stable AP and control     
groups and   we detected that  the AMI group had lower platelet count  
comparing with stable AP and control group. 
         Hence in our study the results were convincing while comparing to 
the Kishk et al
24
 in terms of platelet count. 
 
PLATELET DISTRIBUTION WIDTH AND ACS 
 
In our study mean value of in cases (AMI group and UNSTABLE 
ANGINA group) was 14.5% and controls ( STABLE ANGINA and 
Healthy group)  were 12.9%.  Statistically high significance was detected 
in PDW between cases and control.(p value - <0.001). 
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PLATELET-LARGE CELL RATIO AND ACS 
 
 
In our study mean value of P-LCR in cases (AMI group and 
UNSTABLEANGINA group) was 28.6 and controls ( STABLE 
ANGINA and Healthy group)  were 24.5.  Statistically high significance 
was detected in PDW between cases and control.(p value - <0.001). 
 
OUTCOME AND MPV IN ACS 
 
In our study, 5(10%) patients expired and 45(90%) survived out of 
50 in the ACS group.  No Statistical significance was detected in MPV 
between the outcomes in relation to ACS (p value is .606 i.e. < .05). 
 
CONCLUSION 
 
              It is revealed from the study that  Platelet volume indices is 
increased in cases (AMI group and UNSTABLEANGINA group) in 
comparison  with controls ( STABLE ANGINA and Healthy group). 
Statistical difference has been showed in PVI between cases and controls. 
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LIMITATIONS OF STUDY 
 
 
 
 
 
1) PVI has been found  to be dependent on a number of variables like 
 
a.  The time taken for  analysis after venipuncture,  
 
 
b. The method of analysis,  
 
 
c. The Anticoagulant used  
 
 
d. Temperature of  Specimen storage 
 
 
2) When compared to other studies , the population studied is small.  
 
3) Cardiac biomarkers were not quantified for all the patients.  
 
4) Coronary angiography was not carried out in all the patients.  
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CONCLUSION 
 
 
 
 
 1) Mean platelet volume was found to be increased in ACS group  
1) When compared to Stable angina pectoris and Healthy controls  
Platelet volume indices is found to be increased in patients with 
ACS (AMI group and UNSTABLE ANGINA group ). 
2) Statistically significant difference in platelet volume indices  was 
found  to exist  between cases (AMI group and UNSTABLE 
ANGINA group ) and controls (Stable angina pectoris and Healthy 
controls).   
3) PVI is a feasible and easy reliable test , thus it can be used for the 
initial evaluation of patients admitted with ACS along with other 
cardiac biomarkers. 
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                                            PROFORMA 
NAME:      
AGE:       
SEX:       PHONE NO: 
OCCUPATION: 
ADDRESS: 
EDUCATIONAL STATUS OF THE PATIENT: 
CHIEF COMPLAINTS: 
 
HISTORY OF PRESENTING ILLNESS: 
 
DURATION OF CHEST PAIN: 
PAST HISTROY: DM/HT/PRIOR CAD 
PERSONAL HISTORY: ALCOHOLCONSUMPTION/ SMOKER 
FAMILY HISTORY: 
VITAL SIGN: PULSE 
                         BP 
EXAMINATION OF CVS: 
EXAMINATION OF RS: 
EXAMINATION OF ABDOMEN: 
EXAMINATION OF CNS: 
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DIAGNOSIS: 
 
KILLIP CLASS: 
 
TREATMENT :THROMBOLYSED/HEPARINED 
 
INVESTIGATION: 
1. HEMOGLOBIN 
2. TOTAL COUNT(WBC)  
3. DIFFERENTIAL COUNT  
4. PLATELET COUNT 
5. RENAL FUNCTION TEST 
6. LIVER FUNCTION TEST 
7. LIPID PROFILE 
8. MPV(MEAN PLATELET VOLUME) 
9. PDW(PLATELET DISTRIBUTION WIDTH) 
10. P-LCR(PLATELET LARGE CELL RATIO) 
11. ECG 
12. ECHOCARDIOGRAPHY 
 
DURATION OF HOSPITAL STAY: 
OUTCOME: 
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